Panel participants share an optimistic outlook for integrating new innovations, tacking community-level challenges, and more.

Ash Shehata from KPMG discusses how investors are feeling about the pharma and life sciences industry heading into 2025.

The past few years have been a roller coaster ride for M&A in pharma and biotech. After the highs of the pandemic came ...

Approval follows results from the Phase III ECHO trial, which demonstrated that Calquence plus chemotherapy reduced the risk ...

As part of the Inflation Reduction Act, price negotiations with manufacturers will begin this year, with reduced prices ...

Casey McPherson, Founder and CEO of Chrysalis Genetics, talks about his daughter's rare genetic condition, and how it led him to antisense oligonucleotides (ASOs) and therapeutic development for rare ...

Jason Foster, CEO of Ori Biotech, discusses the difficulties preventing more widespread adoption of these advanced therapies.

Niktimvo marks the first FDA-approved therapy targeting CSF-1R to address inflammation and fibrosis in chronic ...

Cary Claiborne, CEO, Adial Pharmaceuticals, discusses promising results of the AD04-13 study in patients with Alcohol Use Disorder ...

Approval was based on results of the VIVID-1 study, which found that Omvoh demonstrated significant clinical remission and ...

A new offering in collaboration with Progyny, Inc makes fertility/family-building services more accessible and equitable.

Pharmaceutical companies’ direct-to-patient (DTP) programs have recently sparked conversations and criticism in fear of their ...